Publications

Detailed Information

CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines

DC Field Value Language
dc.contributor.authorKim, Young-Yim-
dc.contributor.authorPark, Chul-Kee-
dc.contributor.authorKim, Seung-Ki-
dc.contributor.authorPhi, Ji-Hoon-
dc.contributor.authorKim, Jin-Hyun-
dc.contributor.authorKim, Chae-Yong-
dc.contributor.authorWang, Kyu-Chang-
dc.contributor.authorCho, Byung-Kyu-
dc.date.accessioned2011-10-17T04:34:09Z-
dc.date.available2011-10-17T04:34:09Z-
dc.date.issued2009-
dc.identifier.citationOncol Rep 21:1413-1419,2009en
dc.identifier.issn1021-335X-
dc.identifier.urihttps://hdl.handle.net/10371/74202-
dc.description.abstractCKD-602 7-[2-(N-isopropylamino)ethyl]-(20S)-
camptothecin, belotecan) is a synthetic water-soluble camptothecin
derivative and topoisomerase inhibitor that has been
shown to have clinical anticancer effect against ovarian and
lung cancer. We studied its anticancer effects on four human
glioma cell lines, U87 MG, U343 MG, U251 MG and
LN229. Cell viability was quantified by a modified 2-(2-
methoxy-4-nitropheyl)-3-(4-nitropheyl)-5-(2,4-disulfophenyl)
-2H-tetrazolium, monosodium salt and significant time- and
dose-dependent cytotoxicity was observed in all cell lines.
Susceptibility to CKD-602 at 48 h after treatment varied
among the four cell lines and their IC50 value was as follows:
9.07 nM (95% CI 0.18-37.42) for LN229, 14.57 nM (95% CI
0.86-47.33) for U251 MG, 29.13 nM (95% CI 0.35-101.23)
for U343 MG, and 84.66 nM (95% CI 34.63-148.25) for U87
MG. CKD-602 induced cell cycle arrest at G2 phase and
produced antiproliferative activity and apoptosis in all cell
lines. Thus, CKD-602 showed a significant anticancer effect
on glioma cells in vitro and is a promising candidate for further
studies on malignant gliomas.
en
dc.description.sponsorshipThis study received grant support from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Grant no. 0520300 (B-K. Cho), Korea Science and Engineering Foundation (KOSEF) Grant no. R01-2008-000-20268-0 (S-K. Kim). We thank Chong Kun Dang Pharmaceutical Corporation for providing CKD-602.en
dc.language.isoenen
dc.publisherSpandidos Publicationsen
dc.subjectbelotecanen
dc.subjectcamptothecin analogueen
dc.subjectCKD-602en
dc.subjectmalignant gliomaen
dc.subjecttopoisomerase 1 inhibitoren
dc.titleCKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell linesen
dc.typeArticleen
dc.contributor.AlternativeAuthor김영임-
dc.contributor.AlternativeAuthor박철기-
dc.contributor.AlternativeAuthor김승기-
dc.contributor.AlternativeAuthor피지훈-
dc.contributor.AlternativeAuthor김진현-
dc.contributor.AlternativeAuthor김채용-
dc.contributor.AlternativeAuthor왕규창-
dc.contributor.AlternativeAuthor조병규-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share